“…In addition to Hippo/yap, nuclear factor-kappa B (NF-κB), janus kinases/signal transducer and activator of transcription proteins (JAK/STAT), mitogen-activated protein kinases (MAPK), and phosphatidylinositol 3-kinase (PI3K)/Akt/ mechanistic target of rapamycin (mTOR), investigations on each of these pathways have been the subject of new developments in the last 3 years and are reviewed below. Meanwhile, the role of potential additional factors that drive EMT in cancer (Figure 2) was also highlighted, namely transcriptional factors (TFs) (Vishnoi et al, 2020), translation initiation mechanisms (Bera and Lewis, 2020), miRNAs (Pan et al, 2021) and circular RNAs (circRNAs) (Jiang M. et al, 2021), hypoxia (Peng P. H. et al, 2021), inflammation (Chattopadhyay et al, 2021, and stromal components like tumor-associated macrophages (TAMs) (Han et al, 2021) and cancer-associated fibroblasts (CAFs) (Asif et al, 2021). Other emerging or developing research fields were represented by cancer-associated adipocytes (Liu et al, 2020), endothelial cells and their transformation via endothelial-tomesenchymal transition (EndMT) (Yoshimatsu and Watabe, 2022), and vascular mimicry (Sun et al, 2017).…”